Skip to main content
SpringerLink
Log in

Chemotherapy of Prostatic Carcinoma

  • Conference paper
Malignancies of the Genitourinary Tract

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 126))

  • 43 Accesses

Abstract

In 1941 Huggins and Hodges [22] demonstrated the effect of androgen deprivation on prostatic carcinoma in experimental studies and by clinical observation. Since then, androgen deprivation has become the standard treatment of metastatic prostate cancer. About 25% of patients do not respond to this treatment initially and another 50% show a progression of the disease in the follow-up [47]. That means that more than 75% of patients need an additional treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Al-Sarraf M (1980) Combination of cytoxan adriamycin and cis-platinum (CAP) in patients with advanced prostatic cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 21:198

    Google Scholar 

  2. Ansfield FJ, Schroeder J, Curreri AR (1962) Five years clinical experience with 5-fluorouracil. JAMA 181:295

    Article  PubMed  CAS  Google Scholar 

  3. Beckley S, Wajsman Z, Slack N, Mittelman A, Murphy G (1980) The chemotherapy of prostatic carcinoma. Scand J Urol Nephrol Suppl 55:151

    PubMed  CAS  Google Scholar 

  4. Benson RC Jr, Gill GM, Cummings KB (1983) A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma Semin Oncol 10(3) [Suppl 3]:43

    PubMed  Google Scholar 

  5. Benson RC Jr, Gill GM (1986) Estramustine phosphate compared with diethylstilbestrol. Am J Clin Oncol 9(4):341

    Article  PubMed  Google Scholar 

  6. Berry J, MacDonald RN (1982) Cisplatin, cyclophosphamide and prednisolone therapy for stage D prostatic cancer. Cancer Treat Rep 66:1403

    PubMed  CAS  Google Scholar 

  7. Berry WR, Laszlo J, Cox E, Walker N, Paulson D (1979) Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44:763

    Article  PubMed  CAS  Google Scholar 

  8. Bichler K-H, Flüchter SH (1983) Kriterien in der Progression des Prostatakarzinoms. In: Faul P, Altwein J (eds) Aktuelle Diagnostik und Therapie des Prostatakarzinoms. Erasmus, Santa Barbara, p 213

    Google Scholar 

  9. Buttyan R, Olsson CA (1984) Androgen receptor assays in advanced prostatic cancer. Urol Clin North Am 11:311

    PubMed  CAS  Google Scholar 

  10. Chang AY, Bennet JM, Pandya KJ, Asbury R, McCune C (1989) A study of aminoglutethimide and hydrocortisone in patients with advanced and refractory prostate carcinoma. Am J Clin Oncol 12(4):358

    Article  PubMed  CAS  Google Scholar 

  11. Chlebowski RT, Hestorff R, Sardoff L, Weiner J, Bateman JR (1978) Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123 127), 5-fluorouracil (NSC 19893), and clyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial. Cancer 42:2546

    Article  PubMed  CAS  Google Scholar 

  12. Craig J, Crawford E (1989) Phase II trial of amonafide in advanced prostate cancer: a Southwest Oncology Group Study. Proc Annu Meet Am Soc Clin Oncol 8:A573 (abstr)

    Google Scholar 

  13. deKernion JN, Murphy GP, Priore R (1988) Comparison of flutamide and emcytin hormone-refractory metastatic prostatic cancer. Urology 31:312–317

    Article  PubMed  Google Scholar 

  14. Denis L, Mahler C, Ongena P, Janssen P, De Coster R, Bruynseels J (1990) A phase I/II study with R75251, a novel imidazole derivative in Ml prostate cancer patients in relapse. 9th Congress of the European Association of Urology (EAU), 13-16 June 1990, Amsterdam, p 187 (abstr no 98)

    Google Scholar 

  15. De Smedt E, Denis L, Mahler C, Van Oosterom A, Bruyn E (1990) Suramin: a phase I/II study in patients with prostatic cancer in relapse. 9th Congress of the European Association of Urology (EAU), 13-16 June 1990, Amsterdam, p 379 (abstr no 196)

    Google Scholar 

  16. De Wys WD, Bauer M, Colsky J, Cooper RA, Creeck R, Carbone PP (1977) Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer—progress report. Cancer Treat Rep 61:325

    Google Scholar 

  17. Eagan RT, Hahn RG, Myers RP (1976) Adriamycin (NSC 127127) versus 5-fluorouracil (NSC 19893) and cyclophosphamide (NSC 26271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 60:115

    PubMed  CAS  Google Scholar 

  18. Edsmyr F, Adersson L, Könyves I (1982) Estramustine-phosphate: experimental studies and clinical experience. In: Jacobi GH, Hohenfellner R (eds) Prostate cancer. Williams and Wilkins, Baltimo

    Google Scholar 

  19. Elsenberger MA (1988) Chemotherapy for prostate carcinoma. NCI Monogr 7:151

    Google Scholar 

  20. Fossa SD, Aaronson NK, Newling D and the members of the EORTC Genitourinary Group (1990) Advanced hormone resistant prostatic cancer: preliminary observations on subjective morbidity and palliation. 9th Congress of the European Association of Urology (EAU), 13-16 June 1990, Amsterdam, p 4 (abstr no 2)

    Google Scholar 

  21. Ghosn M, Droz JP, Mahjoubi M, Theodore C, Azab M, Ostronoff M (1989) Phase II trial of ifosfamide (IFO) in hormone-refractory metastatic cancer of the prostate (HRMCP). Proc Annu Meet Am Soc Clin Oncol 8:A549 (abstr)

    Google Scholar 

  22. Graf-Dobberstein C, Rübben H, Deutz FJ, Otto U, Block T, Arregui R (1989) Prospektive multizentrische Phase II Studie zur Wirksamkeit von Cisplatin und Mitomycin in der Therapie des hormonrefraktären Prostatakarzinoms. 41th Congress of the German Society for Urology, 4-7 Oct 1989, Freiburg. Book of abstracts, p 184

    Google Scholar 

  23. Huggins C, Hodges CV (1941) Studies on prostatic cancer: I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293

    CAS  Google Scholar 

  24. Ihde CD, Brunn PA, Cohen MH, Dunnick NR, Eddy JL, Minna JD (1980) Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Cancer 45:1300

    Article  PubMed  CAS  Google Scholar 

  25. Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5:1

    Article  PubMed  CAS  Google Scholar 

  26. Izbicki RM, Amer MH, Al-Sarraf M (1979) Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma. Cancer Treat Rep 63:999

    PubMed  CAS  Google Scholar 

  27. Jones WG, Fossa SD, Denis L, Coninx P, Glashan RW, Akdas A, De Pauw M (1983) An EORTC phase II study of vindesine in advanced prostate cancer. Eur J Cancer Clin Oncol 19:583

    Article  PubMed  CAS  Google Scholar 

  28. Jones WG, Bono AV, Verbaeys A, De Pauw M, Sylvester R, and members of the EORTC (1986) Can the primary tumour be used as the sole parameter for response in phase II chemotherapy studies in metastatic prostate cancer? An EORTC genito-urinary group report. World J Urol 4:176

    Article  Google Scholar 

  29. Jones WG, Fossa SD, Bono AV, Croies JJ, Stoter G, De Pauw M, Sylvester R (1986) Mitomycin C in the treatment of metastatic prostate cancer: report of an EORTC phase II study. World J Urol 4:182

    Article  Google Scholar 

  30. Kasimis B, Miller JB, Kaneshiro CA et al. (1985) Cyclophosphamide versus 5-fluorouracil, doxorubicin and mitomycin C (FAM) in the treatment of hormone resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial. J Clin Oncol 3:385

    PubMed  CAS  Google Scholar 

  31. Keen CW (1980) Half body radiotherapy in the management of metastatic carcinoma of the prostate. J Urol 123:713

    PubMed  CAS  Google Scholar 

  32. Kennealey GT, Marsh JC, Walsh DA et al. (1978) Treatment of advanced carcinoma of the prostate with estramustine and 5-fluorouracil (FU). Proc Am Assoc Cancer Res Am Soc Clin Oncol 19:394

    Google Scholar 

  33. Kühn M, Weißbach L (1990) Primary therapy of metastasized prostate carcinoma with depot GnRH analogue (Zoladex) versus estramustine phosphate (EMP; Estrazyt). 9th Congress of the European Association of Urology (EAU), 13-16 June 1990, Amsterdam, p 254 (abstr no 132)

    Google Scholar 

  34. Kuss R, Khoury S, Richard F et al. (1980) Estramustine phosphate in the treatment of advanced prostatic cancer. Br J Urol 52:29

    Article  PubMed  CAS  Google Scholar 

  35. Labrie F, Dupont A, Bélanger A, Cusan L, Brochu M, Turina E, Pinault S, Lacourciere Y, Emond J (1989) Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration — addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br J Urol 63:634

    Article  PubMed  CAS  Google Scholar 

  36. Leistenschneider W, Nagel R (1980) Zytologisches Regressionsgrading und seine prognostische Bedeutung beim konservativ behandelten Prostatakarzinom. Acta Urol 11:236

    Google Scholar 

  37. Linehan WW, LaRocca R, Stein CY, McClellan W, Cooper M, Weiss G, Choyke P, Cassidy J, Ulrich M, Myers CE (1990) Use of suramin in treatment of patients with advanced prostate carcinoma. 58th Annual Meeting of the American Urology Association (AUA) 13-17 May 1990, New Orleans, p 131 (abstr no 220)

    Google Scholar 

  38. Lloyd RE, Jones SE, Salmon SE et al. (1976) Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. Cancer Treat Rep 60:77

    PubMed  CAS  Google Scholar 

  39. Logethetis CJ, Von Eschenbach AC, Samuels ML, Trindade A, Johnson DE (1982) Doxorubicin, Mitomycin and 5 FU (DMF) in the treatment of hormone resistant stage D prostate cancer: a preliminary report. Cancer Treat Rep 66

    Google Scholar 

  40. Logothetis CJ, Samuels ML, Von Eschenbach AC, Trindade A, Ogden S, Grant C, Johnson DE (1983) Doxorubicin, Mitomycin-C, and 5-Fluorouracil (DMF) in the treatment of metastatic hormone refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1:368

    PubMed  CAS  Google Scholar 

  41. Logothetis CJ, Hossan E, Dexeus FH, Sella A, Amato RJ, Kilbourn RG (1990) Primary combined chemotherapy and hormonal therapy for the treatment of patients with advanced metastatic adenocarcinoma of the prostate. 58th Annual Meeting of the American Urology Association (AUA) 13-17 May 1990, New Orleans, p 481 (abstr no 309)

    Google Scholar 

  42. Mahler C, Keuppens F, Nowé P, Van Erps, Denis L (1988) Prospective study of diethylstilbestrol-diphosphate in the treatment of prostatic cancer in relapse. Urol Int 43(1):47

    Article  Google Scholar 

  43. Merrin C, Etra W, Wajsman Z, Baumgartner G, Murphy G (1976) Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin. J Urol 115:86

    PubMed  CAS  Google Scholar 

  44. Merrin CE (1979) Treatment of genitourinary tumors with cisdichlorodiam-mineplatinum (II): experience in 250 patients. Cancer Treat Rep 63:1579

    PubMed  CAS  Google Scholar 

  45. Mittleman A, Shukla SK, Murphy GP (1976) Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J Urol 115:409

    Google Scholar 

  46. Moore GE, Bross IDJ, Ausman R et al. (1968) Effects of 5-fluorouracil (NSC-19893) in patients with cancer. Eastern Clinical Drug Evaluation Programm. Cancer Chemother Rep 52:641

    PubMed  CAS  Google Scholar 

  47. Moore MR, Troner MB, Desimone P et al. (1986) Phase II evaluation of weekly cisplatin in metastatic hormone resistant prostate cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70:541

    PubMed  CAS  Google Scholar 

  48. Murphy G (1978) Management of advanced cancer of the prostate. In: Skinner DF, De Kernion JB (eds) Genitourinary cancer. Saunders, Philadelphia

    Google Scholar 

  49. Murphy GP, Slack NH, and participants in the National Prostatic Cancer Project (1984) Current status of the National Prostatic Cancer Project treatment protocols. In: Denis L, Murphy GP, Prout GR, Schröder F (eds) Controlled clinical trial in urologic oncology. Raven, New York, p

    Google Scholar 

  50. Muss HB, Howard V, Richards F, White DR, Jackson DV, Cooper MR, Stuart JJ, Resnick MI, Brodkin R, Spurr CL (1981) Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer—a randomized trial. Cancer 47:1949

    Article  PubMed  CAS  Google Scholar 

  51. O’Bryan RM, Luce JK, Talley RW, et al. (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32:1

    Article  PubMed  Google Scholar 

  52. O’Bryan RM, Baker LH, Gottlieb JF et al. (1977) Dose-response evaluation of adriamycin in human neoplasia. Cancer 39:1940

    Article  PubMed  Google Scholar 

  53. Paulson DF, Berry WR, Cox EB et al. (1979) Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy. J Natl Cancer Inst 63:615

    PubMed  CAS  Google Scholar 

  54. Qazi R, Khandekar J.(1983) Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 6:203

    Article  PubMed  CAS  Google Scholar 

  55. Rossof AM, Talley RW, Stephens RL, Thigpen T, Samson MK, Groppe C, Eyre HJ, Fisher R (1979) Phase II evaluation of cis-dichlorodiammineplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs, Southwest Oncology Groups study. Cancer Treat Rep 63:1557

    PubMed  CAS  Google Scholar 

  56. Rübben H (1986) Chemotherapie beim Prostatakarzinom. Onkologisches Forum für Chemotherapie—Schwerpunkt Prostatakarzinome. 2:11

    Google Scholar 

  57. Rübben H, Altwein JE (1987) Das fortgeschrittene Prostatakarzinom—Ein therapeutisches Dilemma? Urologe [A] 26:7

    Google Scholar 

  58. Schmidt JD, Gibbons RP, Johnson DE, Prout GR, Scott WW, Murphy GP (1976) Chemotherapy of advanced prostatic cancer. Urology 6:602

    Article  Google Scholar 

  59. Schmidt JD, Scott WW, Gibbons RP, Johnson DE, Prout GR, Loening SA, Soloway MS, Chu TM, Gaeta GF, Slack NH, Saroff J, Murphy GF (1979) Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of prostate. J Urol 121:185

    PubMed  CAS  Google Scholar 

  60. Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Saroff J, Murphy GP (1976) The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol 116:211

    PubMed  CAS  Google Scholar 

  61. Seppelt U, Sprenger E (1980) Zellkern-DNS-Analysen durch Einzelzell-Fluoreszenz-Zytophotometrie an Prostatakarzinomen vor und während der Therapie. Verh Dtsch Ges Urol 32:68

    Google Scholar 

  62. Smalley RV, Bartolucci AA, Hemstreet G, Hester M (1981) A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and or 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 125:191

    PubMed  CAS  Google Scholar 

  63. Soloway MS, Shippel RM, Ikard M (1979) Cyclophosphamide, doxorubicin hydrochloride, and 5-fluorouracil in advanced carcinoma of the prostate. J Urol 122:637

    PubMed  CAS  Google Scholar 

  64. Soloway MS, De Kernion JB, Gibbons RP, Johnson DE, Leoning SA, Pontes JE, Prout GR, Schmidt JD, Scott WW, Chu TM, Gaeta JF, Slack NH, Murphy GP (1981) Comparision of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone refractory, previously irradiated carcinoma of the prostate. J Urol 125:664

    PubMed  CAS  Google Scholar 

  65. Soloway MS, Beckley S, Brady MF et al. (1983) A comparison of estramustine phosphate, versus cis-platinum alone versus estramustine phosphate plus cisplatinum in patients with advanced hormone refractory prostate cancer who had extensive irradiation to the pelvis or lumbosacral area. J Urol 129:56

    PubMed  CAS  Google Scholar 

  66. Straus MJ, Parmelee J, Olsson C, De Vere White R (1978) Cytoxan, adriamycin and methotrexate (CAM) therapy of stage D prostate cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 19:314

    Google Scholar 

  67. Torti F, Aston D, Lum BL et al. (1983) Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1:477

    PubMed  CAS  Google Scholar 

  68. Torti FM, Shortliffe L, Carter SK et al. (1985) A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer 56:2580

    Article  PubMed  CAS  Google Scholar 

  69. Trachtenberg J, Walsh PC (1982) Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127:466

    PubMed  CAS  Google Scholar 

  70. Tubiana M, Malaise E (1976) Comparison of cell proliferation kinetics in human and experimental tumors: response to irradiation. Cancer Treat Rep 60(12):1887

    PubMed  CAS  Google Scholar 

  71. Witjes FJ, Debruyne FM, Fernandez-del-Moral P, Geboers AD (1989) Ketoconazde high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group. Urology 33(5):411–415

    Article  PubMed  CAS  Google Scholar 

  72. Yagoda A (1979) Phase II trials with cis-diammine-dichloroplatinum (II) in the treatment of urothelial tumors. Cancer Treat Rep 63:1565

    PubMed  CAS  Google Scholar 

  73. Yagoda A, Watson RC, Natale RB et al. (1979) A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 44:1553

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Abteilung, Universitätsklinikum Essen, Hufelandstrasse 55, W-4300, Essen 1, Germany

    H. Rübben, K. Rembrink & T. Johnston

Authors
  1. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Rembrink
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik, Heinrich-Heine-Universität, Moorenstrasse 5, W-4000, Düsseldorf, Germany

    Rolf Ackermann

  2. Medizinische Klinik I, Universität Köln, Joseph-Stelzmann-Strasse 9, W-5000, Köln 41, Germany

    Volker Diehl

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Rübben, H., Rembrink, K., Johnston, T. (1993). Chemotherapy of Prostatic Carcinoma. In: Ackermann, R., Diehl, V. (eds) Malignancies of the Genitourinary Tract. Recent Results in Cancer Research, vol 126. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84583-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84583-3_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-84585-7

  • Online ISBN: 978-3-642-84583-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation